Biogen (BIIB) Receives FDA Approval for TYSABRI High Titer Production
More News related to BIIB
- Biogen Idec to Present at the 2009 Annual Credit Suisse Healthcare Conference
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Jefferies & Co Upgrades Biogen Idec (BIIB) to Buy
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
More News related to FDA
- Hemispherx Biopharma (HEB) Reports a Q3 Loss; Comments on FDA Responses
- Wright Medical Group (WMGI) Announces FDA Approval For CONSERVE Plus Total Hip Resurfacing System
- Vascular Solutions (VASC) Receives 501(k) Clearance from U.S. FDA for GuideLiner Catheter
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- Compugen (CGEN) Announces Discovery of Biomarker CGEN-40001 for Type 2 Diabetes
Biogen Idec (NASDAQ: BIIB) today announced that the U.S. FDA has approved the company's high titer process for the production of its multiple sclerosis drug TYSABRI(R) (natalizumab). Biogen Idec received similar approval from the European Medicines Agency for the high titer process in December 2008. The new, higher-yield process will be used to manufacture TYSABRI at the company's plant in Research Triangle Park.
Related Categories
FDAStocks Mentioned
-0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
